HealthEquity Reports Second Quarter Ended July 31, 2025 Financial Results
HealthEquity (NASDAQ: HQY), the largest HSA custodian in the US, reported strong Q2 FY26 financial results. Revenue reached $325.8 million, up 9% year-over-year, while net income surged 67% to $59.9 million. The company achieved record gross margin of 71% and Adjusted EBITDA of $151.1 million, representing 46% of revenue.
Key metrics include 10.0 million HSAs (up 6% YoY) and Total HSA Assets of $33.1 billion (up 12% YoY). The company repurchased 0.7 million shares for $66.0 million. For FY26, HealthEquity projects revenue between $1.290-1.310 billion and Adjusted EBITDA of $540-560 million.
HealthEquity (NASDAQ: HQY), il principale custode di HSA negli Stati Uniti, ha comunicato solidi risultati finanziari per il secondo trimestre dell'esercizio 2026. I ricavi sono saliti a $325,8 milioni, +9% su base annua, mentre l'utile netto è aumentato del 67% a $59,9 milioni. La società ha registrato un margine lordo record del 71% e un EBITDA rettificato di $151,1 milioni, pari al 46% dei ricavi.
Tra i dati chiave figurano 10,0 milioni di HSA (in aumento del 6% rispetto all'anno precedente) e attività totali HSA per $33,1 miliardi (in crescita del 12% YoY). L'azienda ha riacquistato 0,7 milioni di azioni per un controvalore di $66,0 milioni. Per l'esercizio FY26, HealthEquity stima ricavi tra $1.290 e $1.310 miliardi e un EBITDA rettificato tra $540 e $560 milioni.
HealthEquity (NASDAQ: HQY), el mayor custodio de HSA en EE. UU., presentó sólidos resultados financieros del segundo trimestre del ejercicio 2026. Los ingresos alcanzaron los $325,8 millones, un 9% más interanual, mientras que el beneficio neto se disparó un 67% hasta $59,9 millones. La compañía logró un margen bruto récord del 71% y un EBITDA ajustado de $151,1 millones, equivalente al 46% de los ingresos.
Entre las métricas clave están 10,0 millones de HSA (un 6% más anual) y activos HSA totales por $33,1 mil millones (subida del 12% interanual). La empresa recompró 0,7 millones de acciones por $66,0 millones. Para el año fiscal FY26, HealthEquity proyecta ingresos entre $1.290 y $1.310 mil millones y un EBITDA ajustado de $540–$560 millones.
HealthEquity (NASDAQ: HQY), 미국 최대의 HSA 수탁기관이 2026회계연도 2분기 실적을 발표했습니다. 매출은 $325.8백만으로 전년 대비 9% 증가했고, 순이익은 $59.9백만으로 67% 급증했습니다. 회사는 71%의 사상 최고 총이익률과 매출의 46%에 해당하는 $151.1백만의 조정 EBITDA를 기록했습니다.
핵심 지표로는 1,000만 개의 HSA(전년 대비 6% 증가)와 $331억의 총 HSA 자산(전년 대비 12% 증가)이 있습니다. 또한 자사주 70만 주를 $66.0백만에 되사들였습니다. FY26에 대해 HealthEquity는 매출을 $12.90억–$13.10억, 조정 EBITDA를 $5.40억–$5.60억으로 예상합니다.
HealthEquity (NASDAQ: HQY), le principal dépositaire d'HSA aux États-Unis, a publié de solides résultats pour le deuxième trimestre de l'exercice 2026. Le chiffre d'affaires a atteint 325,8 M$, en hausse de 9% sur un an, tandis que le bénéfice net a bondi de 67% à 59,9 M$. La société a réalisé une marge brute record de 71% et un EBITDA ajusté de 151,1 M$, soit 46% du chiffre d'affaires.
Parmi les indicateurs clés figurent 10,0 millions de HSA (en hausse de 6% sur un an) et 33,1 milliards $ d'actifs HSA (en hausse de 12% en glissement annuel). L'entreprise a racheté 0,7 million d'actions pour 66,0 M$. Pour l'exercice FY26, HealthEquity prévoit un chiffre d'affaires compris entre 1,290 et 1,310 Mds $ et un EBITDA ajusté de 540–560 M$.
HealthEquity (NASDAQ: HQY), der größte HSA-Verwahrer in den USA, meldete starke Ergebnisse für das zweite Quartal des Geschäftsjahres 2026. Der Umsatz belief sich auf $325,8 Mio., ein Plus von 9% gegenüber dem Vorjahr, während der Nettogewinn um 67% auf $59,9 Mio. stieg. Das Unternehmen erzielte eine Rekord-Bruttomarge von 71% und ein bereinigtes EBITDA von $151,1 Mio., was 46% des Umsatzes entspricht.
Zu den wichtigsten Kennzahlen gehören 10,0 Mio. HSAs (plus 6% gegenüber dem Vorjahr) und gesamte HSA-Vermögenswerte in Höhe von $33,1 Mrd. (plus 12% YoY). Das Unternehmen kaufte 0,7 Mio. Aktien für $66,0 Mio. zurück. Für FY26 prognostiziert HealthEquity einen Umsatz zwischen $1.290–1.310 Mrd. und ein bereinigtes EBITDA von $540–560 Mio..
- Revenue growth of 9% YoY to $325.8 million
- Net income increased 67% YoY to $59.9 million
- Record gross margin of 71% and record Adjusted EBITDA of $151.1 million
- HSA Assets grew 12% YoY to $33.1 billion
- Active share repurchase program with $351.8 million remaining authorization
- Strong FY26 guidance with revenue projected at $1.290-1.310 billion
- None.
Insights
HealthEquity delivered strong Q2 results with accelerating profitability and raised its full-year outlook amid favorable HSA legislative tailwinds.
HealthEquity delivered robust financial performance in Q2 FY26, with revenue reaching
The adjusted EBITDA margin expanded 300 basis points to
HealthEquity's core HSA business shows healthy growth with total accounts reaching 10 million, up
The company is confidently returning capital to shareholders through its repurchase program, buying back 0.7 million shares for
Management has raised its full-year guidance, now projecting revenue of
Highlights of the second quarter include:
- Revenue of
$325.8 million , an increase of9% compared to$299.9 million in Q2 FY25. - Net income of
$59.9 million , an increase of67% compared to$35.8 million in Q2 FY25, with non-GAAP net income of$94.6 million , an increase of24% compared to$76.3 million in Q2 FY25. - Net income per diluted share of
$0.68 , an increase of70% compared to$0.40 in Q2 FY25, with non-GAAP net income per diluted share of$1.08 , an increase of26% compared to$0.86 in Q2 FY25. - Adjusted EBITDA of
$151.1 million , an increase of18% compared to$128.3 million in Q2 FY25. - 10.0 million HSAs, an increase of
6% compared to Q2 FY25. - Total HSA Assets of
$33.1 billion , an increase of12% compared to Q2 FY25. - 17.1 million Total Accounts, including both HSAs and complementary CDBs, an increase of
5% compared to Q2 FY25. - The Company repurchased 0.7 million shares of its common stock for
$66.0 million .
DRAPER, Utah, Sept. 02, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian by number of accounts, today announced financial results for its second quarter ended July 31, 2025.
"The HealthEquity team delivered continued momentum during our second quarter with strong
Second quarter financial results
Revenue for the second quarter ended July 31, 2025 was
HealthEquity reported net income of
Adjusted EBITDA was
Account and asset metrics
HSAs as of July 31, 2025 were 10.0 million, an increase of
Total HSA Assets as of July 31, 2025 were
Stock repurchase program
The Company repurchased 0.7 million shares of its common stock for
Business outlook
For the fiscal year ending January 31, 2026, management expects revenues of
See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.
Conference call
HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, September 2, 2025 to discuss the fiscal 2026 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.
Non-GAAP financial information
To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.
- Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
- Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
- Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
- our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
- our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
- our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
- risks relating to our recent CEO transition;
- the impact of increased fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;
- our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
- the significant competition we face and may face in the future, including from those with greater resources than us;
- our reliance on the availability and performance of our technology and communications systems;
- recent and potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
- the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
- potential regulatory changes and changes in the enforcement environment under the new U.S. administration;
- our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
- our reliance on partners and third-party vendors for distribution and important services;
- our ability to develop and implement updated features for our technology platforms and communications systems; and
- our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2025 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations Contact
Richard Putnam
801-727-1000
rputnam@healthequity.com
HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
| (in thousands, except par value) | July 31, 2025 | January 31, 2025 | ||||
| (unaudited) | ||||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 304,461 | $ | 295,948 | ||
| Accounts receivable, net of allowance for doubtful accounts of | 111,164 | 118,006 | ||||
| Prepaid expenses and other current assets | 77,207 | 63,795 | ||||
| Total current assets | 492,832 | 477,749 | ||||
| Property and equipment, net | 3,088 | 3,239 | ||||
| Operating lease right-of-use assets | 39,756 | 43,185 | ||||
| Intangible assets, net | 1,152,456 | 1,204,658 | ||||
| Goodwill | 1,648,145 | 1,648,145 | ||||
| Other assets | 80,401 | 71,574 | ||||
| Total assets | $ | 3,416,678 | $ | 3,448,550 | ||
| Liabilities and stockholders’ equity | ||||||
| Current liabilities | ||||||
| Accounts payable | $ | 9,600 | $ | 14,361 | ||
| Accrued compensation | 32,482 | 69,330 | ||||
| Accrued liabilities | 64,543 | 62,631 | ||||
| Operating lease liabilities | 9,950 | 10,001 | ||||
| Total current liabilities | 116,575 | 156,323 | ||||
| Long-term liabilities | ||||||
| Long-term debt, net of issuance costs | 1,006,834 | 1,056,301 | ||||
| Operating lease liabilities, non-current | 38,240 | 42,219 | ||||
| Other long-term liabilities | 21,993 | 22,962 | ||||
| Deferred tax liability | 86,615 | 55,834 | ||||
| Total long-term liabilities | 1,153,682 | 1,177,316 | ||||
| Total liabilities | 1,270,257 | 1,333,639 | ||||
| Commitments and contingencies | ||||||
| Stockholders’ equity | ||||||
| Preferred stock, | — | — | ||||
| Common stock, | 9 | 9 | ||||
| Additional paid-in capital | 1,919,312 | 1,905,628 | ||||
| Accumulated other comprehensive income | 203 | — | ||||
| Accumulated earnings | 226,897 | 209,274 | ||||
| Total stockholders’ equity | 2,146,421 | 2,114,911 | ||||
| Total liabilities and stockholders’ equity | $ | 3,416,678 | $ | 3,448,550 | ||
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations (unaudited)
| Three months ended July 31, | Six months ended July 31, | ||||||||||||||
| (in thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| Revenue | |||||||||||||||
| Service revenue | $ | 117,873 | $ | 116,720 | $ | 237,657 | $ | 234,934 | |||||||
| Custodial revenue | 159,876 | 138,684 | 316,331 | 260,328 | |||||||||||
| Interchange revenue | 48,086 | 44,524 | 102,691 | 92,263 | |||||||||||
| Total revenue | 325,835 | 299,928 | 656,679 | 587,525 | |||||||||||
| Cost of revenue | |||||||||||||||
| Service costs | 75,156 | 76,915 | 163,161 | 159,262 | |||||||||||
| Custodial costs | 11,137 | 10,108 | 21,884 | 19,165 | |||||||||||
| Interchange costs | 6,947 | 8,853 | 14,728 | 17,908 | |||||||||||
| Total cost of revenue | 93,240 | 95,876 | 199,773 | 196,335 | |||||||||||
| Gross profit | 232,595 | 204,052 | 456,906 | 391,190 | |||||||||||
| Operating expenses | |||||||||||||||
| Sales and marketing | 19,922 | 21,525 | 45,906 | 45,019 | |||||||||||
| Technology and development | 64,804 | 58,580 | 126,240 | 114,670 | |||||||||||
| General and administrative | 29,990 | 32,260 | 55,526 | 70,496 | |||||||||||
| Amortization of acquired intangible assets | 27,001 | 30,981 | 54,003 | 56,526 | |||||||||||
| Merger integration | 1,266 | 1,777 | 2,541 | 3,920 | |||||||||||
| Total operating expenses | 142,983 | 145,123 | 284,216 | 290,631 | |||||||||||
| Income from operations | 89,612 | 58,929 | 172,690 | 100,559 | |||||||||||
| Other expense | |||||||||||||||
| Interest expense | (14,955 | ) | (15,427 | ) | (29,813 | ) | (27,222 | ) | |||||||
| Other income, net | 3,391 | 3,114 | 6,124 | 6,518 | |||||||||||
| Total other expense | (11,564 | ) | (12,313 | ) | (23,689 | ) | (20,704 | ) | |||||||
| Income before income taxes | 78,048 | 46,616 | 149,001 | 79,855 | |||||||||||
| Income tax provision | 18,194 | 10,794 | 35,232 | 15,220 | |||||||||||
| Net income | $ | 59,854 | $ | 35,822 | $ | 113,769 | $ | 64,635 | |||||||
| Net income per share: | |||||||||||||||
| Basic | $ | 0.69 | $ | 0.41 | $ | 1.31 | $ | 0.74 | |||||||
| Diluted | $ | 0.68 | $ | 0.40 | $ | 1.29 | $ | 0.73 | |||||||
| Weighted-average number of shares used in computing net income per share: | |||||||||||||||
| Basic | 86,550 | 87,131 | 86,601 | 86,805 | |||||||||||
| Diluted | 87,746 | 88,646 | 88,153 | 88,606 | |||||||||||
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of comprehensive income (unaudited)
| Three months ended July 31, | Six months ended July 31, | ||||||||||||||
| (in thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| Net income | $ | 59,854 | $ | 35,822 | $ | 113,769 | $ | 64,635 | |||||||
| Other comprehensive income | |||||||||||||||
| Cash flow hedges | |||||||||||||||
| Net unrealized gains, net of income tax expense | 203 | — | 203 | — | |||||||||||
| Total other comprehensive income | 203 | — | 203 | — | |||||||||||
| Comprehensive income | $ | 60,057 | $ | 35,822 | $ | 113,972 | $ | 64,635 | |||||||
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
| Six months ended July 31, | |||||||
| (in thousands) | 2025 | 2024 | |||||
| Cash flows from operating activities: | |||||||
| Net income | $ | 113,769 | $ | 64,635 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 77,195 | 82,548 | |||||
| Stock-based compensation | 33,404 | 53,594 | |||||
| Amortization of debt discount and issuance costs | 533 | 1,428 | |||||
| Deferred taxes | 30,711 | (5,204 | ) | ||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable, net | 6,842 | (3,561 | ) | ||||
| Prepaid expenses and other current and non-current assets | (20,650 | ) | (9,345 | ) | |||
| Operating lease right-of-use assets | 3,339 | 3,365 | |||||
| Accrued compensation | (35,032 | ) | (12,706 | ) | |||
| Accounts payable, accrued liabilities, and other current liabilities | (3,785 | ) | 7,267 | ||||
| Operating lease liabilities, non-current | (3,951 | ) | (3,840 | ) | |||
| Other long-term liabilities | (1,771 | ) | (4,623 | ) | |||
| Net cash provided by operating activities | 200,604 | 173,558 | |||||
| Cash flows from investing activities: | |||||||
| Purchases of software and capitalized software development costs | (26,464 | ) | (25,329 | ) | |||
| Purchases of property and equipment | (859 | ) | (1,462 | ) | |||
| Acquisitions of HSA portfolios | — | (452,241 | ) | ||||
| Net cash used in investing activities | (27,323 | ) | (479,032 | ) | |||
| Cash flows from financing activities: | |||||||
| Principal payments on long-term debt | (50,000 | ) | — | ||||
| Repurchases of common stock | (125,810 | ) | — | ||||
| Proceeds from long-term debt | — | 225,000 | |||||
| Settlement of client-held funds obligation, net | 596 | (828 | ) | ||||
| Proceeds from exercise of common stock options | 10,446 | 4,216 | |||||
| Net cash provided by (used in) financing activities | (164,768 | ) | 228,388 | ||||
| Increase (decrease) in cash and cash equivalents | 8,513 | (77,086 | ) | ||||
| Beginning cash and cash equivalents | 295,948 | 403,979 | |||||
| Ending cash and cash equivalents | $ | 304,461 | $ | 326,893 | |||
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)
| Six months ended July 31, | |||||||
| (in thousands) | 2025 | 2024 | |||||
| Supplemental cash flow data: | |||||||
| Interest expense paid in cash | $ | 28,362 | $ | 26,970 | |||
| Income tax payments, net | 6,507 | 13,471 | |||||
| Supplemental disclosures of non-cash investing and financing activities: | |||||||
| Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation | 3,380 | 3,370 | |||||
| Purchases of property and equipment included in accounts payable or accrued liabilities | 155 | 70 | |||||
| Repurchases of common stock included in accrued liabilities | 1,246 | — | |||||
| Non-cash purchase consideration related to acquisitions of HSA portfolios | — | 20,325 | |||||
Stock-based compensation expense (unaudited)
Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:
| Three months ended July 31, | Six months ended July 31, | |||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||
| Cost of revenue | $ | 3,114 | $ | 2,934 | $ | 6,501 | $ | 7,459 | ||||
| Sales and marketing | 1,529 | 3,850 | 6,399 | 8,173 | ||||||||
| Technology and development | 5,732 | 6,454 | 11,652 | 12,394 | ||||||||
| General and administrative | 8,693 | 8,336 | 8,852 | 25,568 | ||||||||
| Total stock-based compensation expense | $ | 19,068 | $ | 21,574 | $ | 33,404 | $ | 53,594 | ||||
Total Accounts (unaudited)
| (in thousands, except percentages) | July 31, 2025 | July 31, 2024 | % Change | January 31, 2025 | |||||
| HSAs | 9,989 | 9,383 | 6 | % | 9,889 | ||||
| New HSAs from sales - Quarter-to-date | 163 | 187 | (13 | )% | 471 | ||||
| New HSAs from sales - Year-to-date | 312 | 382 | (18 | )% | 1,040 | ||||
| New HSAs from acquisitions - Year-to-date | — | 616 | * | 616 | |||||
| HSAs with investments | 782 | 711 | 10 | % | 753 | ||||
| CDBs | 7,153 | 6,898 | 4 | % | 7,144 | ||||
| Total Accounts | 17,142 | 16,281 | 5 | % | 17,033 | ||||
| Average Total Accounts - Quarter-to-date | 17,044 | 16,214 | 5 | % | 16,677 | ||||
| Average Total Accounts - Year-to-date | 17,083 | 16,066 | 6 | % | 16,302 | ||||
* Not meaningful
HSA Assets (unaudited)
| (in millions, except percentages) | July 31, 2025 | July 31, 2024 | % Change | January 31, 2025 | ||||||||
| HSA cash | $ | 17,035 | $ | 16,368 | 4 | % | $ | 17,435 | ||||
| HSA investments | 16,102 | 13,099 | 23 | % | 14,676 | |||||||
| Total HSA Assets | 33,137 | 29,467 | 12 | % | 32,111 | |||||||
| Average daily HSA cash - Quarter-to-date | 17,017 | 16,363 | 4 | % | 16,634 | |||||||
| Average daily HSA cash - Year-to-date | 17,149 | 15,875 | 8 | % | 16,206 | |||||||
The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of July 31, 2025:
| Year ending January 31, (in billions, except percentages) | HSA cash expected to reprice | Average annualized yield | ||||
| Remainder of 2026 | $ | 1.3 | 1.7 | % | ||
| 2027 | 4.1 | 2.0 | % | |||
| 2028 | 2.2 | 4.1 | % | |||
| 2029 | 1.5 | 3.7 | % | |||
| Thereafter | 7.3 | 4.5 | % | |||
| Total (1) | $ | 16.4 | 3.5 | % | ||
(1) Excludes
Client-held funds (unaudited)
| (in millions, except percentages) | July 31, 2025 | July 31, 2024 | % Change | January 31, 2025 | ||||||||
| Client-held funds | $ | 818 | $ | 817 | 0 | % | $ | 896 | ||||
| Average daily Client-held funds - Quarter-to-date | 884 | 860 | 3 | % | 798 | |||||||
| Average daily Client-held funds - Year-to-date | 893 | 850 | 5 | % | 817 | |||||||
Reconciliation of net income to Adjusted EBITDA (unaudited)
| Three months ended July 31, | Six months ended July 31, | ||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| Net income | $ | 59,854 | $ | 35,822 | $ | 113,769 | $ | 64,635 | |||||||
| Interest income | (3,364 | ) | (3,103 | ) | (6,097 | ) | (6,984 | ) | |||||||
| Interest expense | 14,955 | 15,427 | 29,813 | 27,222 | |||||||||||
| Income tax provision | 18,194 | 10,794 | 35,232 | 15,220 | |||||||||||
| Depreciation and amortization | 11,453 | 12,629 | 23,192 | 26,022 | |||||||||||
| Amortization of acquired intangible assets | 27,001 | 30,981 | 54,003 | 56,526 | |||||||||||
| Stock-based compensation expense | 19,068 | 21,574 | 33,404 | 53,594 | |||||||||||
| Merger integration expenses | 1,266 | 1,777 | 2,541 | 3,920 | |||||||||||
| Amortization of incremental costs to obtain a contract | 1,951 | 1,681 | 3,877 | 3,313 | |||||||||||
| Costs associated with unused office space | 723 | 806 | 1,575 | 1,596 | |||||||||||
| Other | (27 | ) | (101 | ) | (27 | ) | 658 | ||||||||
| Adjusted EBITDA | $ | 151,074 | $ | 128,287 | $ | 291,282 | $ | 245,722 | |||||||
Net income as a percentage of revenue (unaudited)
| Three months ended July 31, | Six months ended July 31, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change | |||||||||||||||||||
| Net income | $ | 59,854 | $ | 35,822 | $ | 24,032 | 67 | % | $ | 113,769 | $ | 64,635 | $ | 49,134 | 76 | % | |||||||||||
| As a percentage of revenue | 18 | % | 12 | % | 17 | % | 11 | % | |||||||||||||||||||
Adjusted EBITDA as a percentage of revenue (unaudited)
| Three months ended July 31, | Six months ended July 31, | ||||||||||||||||||||||||||
| (in thousands, except percentages) | 2025 | 2024 | $ Change | % Change | 2025 | 2024 | $ Change | % Change | |||||||||||||||||||
| Adjusted EBITDA | $ | 151,074 | $ | 128,287 | $ | 22,787 | 18 | % | $ | 291,282 | $ | 245,722 | $ | 45,560 | 19 | % | |||||||||||
| As a percentage of revenue | 46 | % | 43 | % | 44 | % | 42 | % | |||||||||||||||||||
Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)
| Outlook for the year ending | ||
| (in millions) | January 31, 2026 | |
| Net income | ||
| Interest income | (11) | |
| Interest expense | 56 | |
| Income tax provision | 62 - 67 | |
| Depreciation and amortization | 48 | |
| Amortization of acquired intangible assets | 108 | |
| Stock-based compensation expense | 75 | |
| Merger integration expenses | 6 | |
| Amortization of incremental costs to obtain a contract | 8 | |
| Costs associated with unused office space | 3 | |
| Adjusted EBITDA | ||
Reconciliation of net income to non-GAAP net income (unaudited)
| Three months ended July 31, | Six months ended July 31, | |||||||||||
| (in thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||
| Net income | $ | 59,854 | $ | 35,822 | $ | 113,769 | $ | 64,635 | ||||
| Income tax provision | 18,194 | 10,794 | 35,232 | 15,220 | ||||||||
| Income before income taxes - GAAP | 78,048 | 46,616 | 149,001 | 79,855 | ||||||||
| Non-GAAP adjustments: | ||||||||||||
| Amortization of acquired intangible assets | 27,001 | 30,981 | 54,003 | 56,526 | ||||||||
| Stock-based compensation expense | 19,068 | 21,574 | 33,404 | 53,594 | ||||||||
| Merger integration expenses | 1,266 | 1,777 | 2,541 | 3,920 | ||||||||
| Costs associated with unused office space | 723 | 806 | 1,575 | 1,596 | ||||||||
| Loss on extinguishment of debt | — | — | — | — | ||||||||
| Total adjustments to income before income taxes - GAAP | 48,058 | 55,138 | 91,523 | 115,636 | ||||||||
| Income before income taxes - Non-GAAP | 126,106 | 101,754 | 240,524 | 195,491 | ||||||||
| Income tax provision - Non-GAAP (1) | 31,526 | 25,439 | 60,130 | 48,873 | ||||||||
| Non-GAAP net income | 94,580 | 76,315 | 180,394 | 146,618 | ||||||||
| Diluted weighted-average shares | 87,746 | 88,646 | 88,153 | 88,606 | ||||||||
| GAAP net income per diluted share | $ | 0.68 | $ | 0.40 | $ | 1.29 | $ | 0.73 | ||||
| Non-GAAP net income per diluted share | $ | 1.08 | $ | 0.86 | $ | 2.05 | $ | 1.65 | ||||
(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was
Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)
| Outlook for the year ending | ||
| (in millions, except per share data) | January 31, 2026 | |
| Net income | ||
| Income tax provision | 62 - 67 | |
| Income before income taxes - GAAP | 247 - 267 | |
| Non-GAAP adjustments: | ||
| Amortization of acquired intangible assets | 108 | |
| Stock-based compensation expense | 75 | |
| Merger integration expenses | 6 | |
| Costs associated with unused office space | 3 | |
| Total adjustments to income before income taxes - GAAP | 192 | |
| Income before income taxes - Non-GAAP | 439 - 459 | |
| Income tax provision - Non-GAAP (1) | 110 - 115 | |
| Non-GAAP net income | ||
| Diluted weighted-average shares | 88 | |
| GAAP net income per diluted share (2) | ||
| Non-GAAP net income per diluted share (2) | ||
(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was
(2) GAAP and non-GAAP net income per diluted share may not calculate due to rounding.
Certain terms
| Term | Definition |
| HSA | Health Savings Account, which is a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis. |
| CDB | Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits. |
| HSA member | Consumers with HSAs that we serve. |
| Total HSA Assets | HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments held by our custodial investment fund partner. |
| Client | Our employer clients. |
| Total Accounts | The sum of HSAs and CDBs on our platforms. |
| Client-held funds | Deposits held on behalf of our Clients to facilitate administration of our CDBs. |
| Network Partner | Our health plan partners, benefits administrators, and retirement plan recordkeepers. |
| Adjusted EBITDA | Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. |
| Non-GAAP net income | Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate. |
| Non-GAAP net income per diluted share | Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding. |
FAQ
What were HealthEquity's (HQY) Q2 2026 earnings results?
How many HSA accounts does HealthEquity manage in Q2 2026?
What is HealthEquity's (HQY) full year 2026 guidance?
How much stock did HealthEquity (HQY) repurchase in Q2 2026?
What is the total value of HSA assets under HealthEquity's management?
